Position in RLAY
as of Mar 31, 2026
· filed Apr 29, 2026
Position Value
$324,141
+$94,529 QoQ
Shares Held
32,577
+20.0% QoQ
Ownership
0.015%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in RLAY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Brooklyn Investment Group holds $22,842,973 across 42 Biotechnology names. RLAY ranks #27 (1.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
6,245 | $2,788,642 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,889 | $1,459,516 | |
| 3 | ROIV |
Roivant Sciences Ltd.
|
50,312 | $1,393,642 | |
| 4 | ARGX |
Argenx SE
|
1,697 | $1,239,234 | |
| 5 | MRNA |
Moderna, Inc.
|
23,110 | $1,173,988 | |
| 6 | GMAB |
Genmab A/S
|
35,823 | $961,131 | |
| 7 | ASND |
Ascendis Pharma A/S
|
4,072 | $931,388 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
8,994 | $874,666 |
All Filings in RLAY
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $324,141 | 32,577 | Shares | Defined | 2026-04-29 | |
| 2025-12-31 | $229,612 | 27,141 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $511,283 | 97,947 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $349,657 | 101,057 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $15,864 | 6,055 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $11,540 | 2,801 | Shares | Defined | 2025-01-15 | |
| No filing history on record for this holder in this stock. | ||||||